{"id":"da198e70-ddbb-5e73-bb36-1f9158e2c085","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-mi-function","predicate":"no_demonstrated_benefit","statement":"VINTAGE MI found no significant improvement in ejection fraction or vascular stiffness over six months.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"d0859b45-58aa-5382-aca4-fd2b010e9e3d","mechanism_event_label":"A plausible pathway did not deliver the intended clinical benefit.","subject":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"object":{"id":"609f6402-143e-5208-98ee-af217a2cb6e3","slug":"post-mi-ejection-fraction","display_name":"Left-ventricular ejection fraction after myocardial infarction","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"d0859b45-58aa-5382-aca4-fd2b010e9e3d","stable_key":"fd37d270-3395-56d6-9f1c-ddda56e606f6:arg-mi-function-event","event_type":"observed_relationship","label":"A plausible pathway did not deliver the intended clinical benefit.","description":"VINTAGE MI found no significant improvement in ejection fraction or vascular stiffness over six months.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"eeca3c9e-7749-5677-b7bd-37fe8f7c228d","slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"609f6402-143e-5208-98ee-af217a2cb6e3","slug":"post-mi-ejection-fraction","display_name":"Left-ventricular ejection fraction after myocardial infarction","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"153 recent STEMI patients; target 3 g three times daily versus placebo plus usual therapy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Post-infarction setting; a biochemical NO pathway is not evidence of benefit here.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Arginine collection; tissue, species, dose and formulation distinctions retained.","comparator":null,"unit":null,"notes":"","entity":{"slug":"arginine","display_name":"L-Arginine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A plausible pathway did not deliver the intended clinical benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16391217/ · DOI 10.1001/jama.295.1.58","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"2bcf4e83-32bc-5bf9-acb3-662ccf6661df","evidence_kind":"source_excerpt","locator":"Lines 374-380","start_line":374,"end_line":380,"excerpt":"## arg-mi-function\nA plausible pathway did not deliver the intended clinical benefit.\nVINTAGE MI found no significant improvement in ejection fraction or vascular stiffness over six months.\nModel: 153 recent STEMI patients; target 3 g three times daily versus placebo plus usual therapy.\nLimitations: Post-infarction setting; a biochemical NO pathway is not evidence of benefit here.\nEvidence access: Primary abstract\nL-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. · 2006 · https://pubmed.ncbi.nlm.nih.gov/16391217/ · DOI 10.1001/jama.295.1.58","model_system":"153 recent STEMI patients; target 3 g three times daily versus placebo plus usual therapy.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; primary evidence access stated per claim.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"bb9a67ea-904f-5b8a-93a4-459081212bdd","stable_key":"import-fd37d270-3395-56d6-9f1c-ddda56e606f6","title":"L-Arginine: transport, metabolic branches, nutrient interactions, availability and discovery questions (2026-09-18)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"ec0e9a3fb72b7485534e4372a074ac7624a399ff962e55690eb462217b5149ec","revision_id":"af027270-5535-51ae-85ff-9c76c518c962","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}